Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 2,377 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility Evaluation of Daily Disposable Toric Soft Contact Lenses Manufactured With an Alternative Hydration Process

NCT05427539
View directory record Official record
Conditions
Ocular Physiology
Interventions
TEST LENS, CONTROL LENS
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
6
States / cities
Jacksonville, Florida • Maitland, Florida • Vestal, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 23, 2026, 2:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Triton Reference Database

NCT03067675
View directory record Official record
Conditions
Healthy Eyes
Interventions
Topcon DRI OCT Triton (plus)
Device
Lead sponsor
Topcon Corporation
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
6
States / cities
Anaheim, California • Pasadena, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 23, 2026, 2:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Aqueous Outflow Facility Changes With Posture

NCT00571012
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 23, 2026, 2:23 PM EDT
Not listed Not applicable Interventional

Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty

NCT00567411
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
brimonidine 0.1%, Apraclonidine 0.5%
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

NCT01157364
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
36
States / cities
Artesia, California • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Study of Topical Ocular PAN-90806 in PDR

NCT02475109
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
PAN-90806 Ophthalmic Solution
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Harlingen, Texas • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Phase 4 Interventional

Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment

NCT00680498
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab, Ranibizumab plus Photodynamic therapy
Drug
Lead sponsor
Illinois Retina Associates
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults

NCT04657172
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine Ophthalmic, Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
40 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
Azusa, California • Newport Beach, California • Fort Collins, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 23, 2026, 2:23 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

NCT06856577
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurolens Headache Study

NCT05070767
View directory record Official record
Conditions
Binocular Vision Disorder, Convergence Insufficiency, Headache, Computer Vision Syndrome
Interventions
Neurolens spectacle lens, Placebo spectacle lens
Device
Lead sponsor
Neurolens Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Conyers, Georgia • Perry, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Phase 2Phase 3 Interventional

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity

NCT01203436
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Blindness
Interventions
Supplemental Oxygen Management, Conventional Oxygen Management
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
9
States / cities
Palo Alto, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 23, 2026, 2:23 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

NCT04289571
View directory record Official record
Conditions
Cone-Rod Degeneration, Rod-Cone Degeneration
Interventions
VR Mobility Tool
Diagnostic Test
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
5 Years to 120 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Brief Cognitive Behavioral Therapy for People With Physical Disabilities

NCT05695430
View directory record Official record
Conditions
Suicide, Suicide, Attempted, Suicidal Ideation, Disability Physical, Disability Hearing, Disability, Vision
Interventions
Brief Cognitive Behavioral Therapy for People with Physical Disabilities
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 2:23 PM EDT
Recruiting Phase 2 Interventional

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

NCT02521311
View directory record Official record
Conditions
Optic Neuritis
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units

NCT01825057
View directory record Official record
Conditions
See One, Do One, Order One
Interventions
See One, Do One, Order One
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

NCT00089765
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Agreement and Precision Study of the Nidek Mirante

NCT04318132
View directory record Official record
Conditions
Glaucoma, Retinal Disease, Corneal Disease
Interventions
Nidek Mirante, Optovue RTVue XR Avanti, Optos P200DTx
Device
Lead sponsor
Nidek Co. LTD.
Industry
Eligibility
22 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 23, 2026, 2:23 PM EDT
Completed No phase listed Observational

Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study

NCT01728883
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Home vision monitoring using myVisionTrack®
Device
Lead sponsor
Vital Art and Science Incorporated
Industry
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 23, 2026, 2:23 PM EDT
Not yet recruiting Not applicable Interventional

TearCare in Young Adults

NCT07579156
View directory record Official record
Conditions
Meibomian Gland Dysfunction (Disorder)
Interventions
TearCare®
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 2:23 PM EDT
Active, not recruiting Phase 2 Interventional

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions
QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 2:23 PM EDT
Not yet recruiting No phase listed Observational

Vascular Endothelial Inflammation and Health Status In INOCA (VISION-INOCA)

NCT07586241
View directory record Official record
Conditions
Ischemia and Non-obstructive Coronary Arteries
Interventions
Invasive coronary angiography, Coronary Artery Endothelial Cell Sampling, Fitbit, Invasive coronary function testing
Procedure · Device · Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Young Plasma Transfusions for Progressive Supranuclear Palsy

NCT02460731
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Fresh Frozen Plasma
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 23, 2026, 2:23 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

QST for Corneal Nerve Function

NCT05758753
View directory record Official record
Conditions
Corneal Disease, Neuropathy, Dry Eye Disease, Neurotrophic Keratitis
Interventions
Quantitative Sensory Test
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 23, 2026, 2:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

TRK-3 Conformance to Standards for Tonometers

NCT06247072
View directory record Official record
Conditions
Glaucoma
Interventions
Tonometer
Device
Lead sponsor
Topcon Corporation
Industry
Eligibility
22 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
La Mesa, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 23, 2026, 2:23 PM EDT